Niacin or ezetimibe for patients with, or at risk of coronary heart disease

Abstract

Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy. This paper will examine two of the more popular secondary agents, ezetimibe and niacin, and describe their research data and potential for usefulness in further reducing cardiovascular events. © The author(s), publisher and licensee Libertas Academica Ltd.